The Odyssey

Video

What dementia treatment makes an interesting appearance in classical literature?

John J. Miller, MD, talks about approved treatments for early, mild-to-moderate dementia, one of which makes an appearance in "The Odyssey."

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Related Videos
Video 2 - "Exploration into the Management of the Three Symptom Domains of Schizophrenia"
dementia
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
Related Content
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review

April 3rd 2024
Article
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From the Pages of Psychiatric Times: March 2024

March 30th 2024
Article
From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

The Week in Review: March 11-15

March 16th 2024
Article
“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

Mild Cognitive Impairment and Serotonin System Degeneration

March 14th 2024
Article
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

February 20th 2024
Article
From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

The Week in Review: February 12-16

February 17th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.